Valion Bio, Inc. (VBIO) Stock Score, Valuation & Financial Research

Valion Bio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for VBIO

Valion Bio, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.58. These figures are a research snapshot, not a buy or sell recommendation.

What Valion Bio, Inc. does

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Valion Bio is a clinical-stage biopharmaceutical company that generates no revenue. It is currently focused on the development of its lead product candidate, Entolimod, a TLR5 agonist, and has not yet obtained regulatory approval or commercialized any products.

Products and services

  • The company is developing Entolimod and Entolasta, which are TLR5 agonist product candidates intended for the treatment of radiation injury and other indications.

Brands and product families

  • Entolimod — Lead TLR5 agonist product candidate. Source
  • Entolasta — Second-generation TLR5 agonist compound. Source

Business strengths to evaluate

  • Exclusive license rights to TLR5 agonist franchise including Entolimod and Entolasta Source

Business risks and research considerations

  • History of net losses and negative cash flows with no expectation of revenue until regulatory approval Source
  • Dependence on successful clinical development and regulatory approval of product candidates Source

Sources: Company research source · Entolasta

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

VBIO financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.58
Market capitalization:
10.66M (currency not supplied)
Revenue:
USD -156K
Net income:
USD -18.75M
Free cash flow:
USD -7.04M
Cash:
USD 2.11M
Total debt:
USD 17.41M
EPS:
USD -56.74

What stands out

  • Free cash flow is USD -7.04M, negative for the stored period.
  • The balance sheet shows USD 2.11M of cash versus USD 17.41M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 15.3M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for VBIO

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can VBIO fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is VBIO's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for VBIO to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of VBIO's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research VBIO

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.